United States Patent 10,436,802 (Spinal Muscular Atrophy) Intrathecal 18-mer 2′-MOE Phosphorothioate Antisense Method: Claim Scope, Coverage Gaps, and Patent Landscape
US Drug Patent 10,436,802 is a method-of-treatment patent for spinal muscular atrophy (SMA) using an intrathecal administration regimen of a highly specific 18-linked-nucleoside antisense oligonucleotide with a defined chemical and sequence definition (including 18 nucleosides, phosphorothioate internucleoside linkages, 2′-MOE nucleosides, and 5-methylcytosine). The claim set is built to capture variations on dosing timing (loading and maintenance) and delivery (intrathecal bolus, needle delivery), with additional dependent claim narrowing to 2.4 mg/mL and 5.0 mL dosing volume, and to SMA type I-IV and broad age windows.
Below is the scope and claims analysis driven directly from the claim language you provided, followed by a technical coverage map of what is captured versus what is left open for design-arounds and competitive patentability risks.
What does US Patent 10,436,802 claim for SMA treatment using intrathecal antisense? (Independent claim 1 core limitations)
Featured snippet: What must be present for infringement?
Claim 1 requires all of the following in one method practice:
- A human subject with one or more symptoms associated with SMA.
- Administration by intrathecal injection of an antisense compound comprising an antisense oligonucleotide.
- The oligonucleotide is an 18-linked nucleoside molecule.
- The oligonucleotide has nucleobase sequence SEQ ID NO:1.
- Each internucleoside linkage is phosphorothioate.
- Each nucleoside is a 2′-MOE nucleoside.
- Each cytosine is 5-methyl cytosine.
- The dose regimen is 12 mg per dose with specified relative timing:
- First dose: 12 mg
- Second dose: 12 mg 12–18 days after first
- Third dose: 12 mg 25–35 days after first
Claim 1 structure and how it limits scope
Claim 1 is drafted as a regimen + molecular-identity claim. That combination is strong against partial design-arounds because a potential infringer must avoid either:
- the molecular identity (sequence and backbone/chemistry descriptors), or
- the regimen timing/amount and intrathecal route.
In practice, this means claim 1 is not a generic “intrathecal antisense for SMA” claim. It is a specific “this exact oligonucleotide chemistry and sequence delivered intrathecally with this induction schedule.”
How broad are the regimen limits in claim 1 (12–18 days and 25–35 days) and what dosing window is actually captured?
Dosing windows captured by claim 1
- Second dose: 12 mg administered 12–18 days after the first dose
- Third dose: 12 mg administered 25–35 days after the first dose
This is not a single fixed schedule. It is a time range schedule. That tends to:
- increase practical infringement likelihood if the dosing schedule in practice falls within those windows,
- reduce value of “off-by-a-few-days” noninfringement strategies.
Dependent claim 2 narrows but also overlaps
Claim 2 recites:
- Second dose approximately 15 days after first
- Third dose approximately 29 days after first
The “approximately” language creates a practical buffer around the “about” anchor values, but because claim 2 is dependent, it still requires claim 1’s chemistry/identity limitations. Claim 2 therefore functions as a preferred embodiment within claim 1’s broader windows.
What are the claim 3 and 10 “maintenance dose” structures and how do they expand coverage beyond induction?
Claim 3: maintenance dosing is required or optional depending on claim dependency
Claim 3 is dependent on claim 1 and states: “wherein the subject is further administered at least one maintenance dose.”
This converts claim 3 into a narrower set of methods than claim 1:
- It is not limited to a particular maintenance day in claim 3 alone (because it says “at least one”),
- But any method practicing claim 1 plus any maintenance dosing could fall within claim 3.
Claim 10: specific maintenance timing (178–188 days)
Claim 10 recites maintenance dose comprising:
- 12 mg at 178–188 days after administration of the first dose.
This is a key narrowing claim. It captures maintenance schedules around that window. A competitor deviating outside that window would fall out of claim 10 but could still potentially practice claim 3 if they have “at least one maintenance dose” without the specific timing recited in claim 10 (assuming all other requirements are met).
Claim 11–12: expanded 4th and 5th dose maintenance structure
Claim 11 adds:
- 4th dose: 12 mg at approximately 64 days after first dose
- 5th dose: 12 mg at approximately 183 days after first dose
Claim 12 mirrors the same for claim 2 (dependent on the fixed approximately 15/29 day induction anchor).
These claims are designed to cover multi-dose maintenance ladders that include an intermediate 64-day timepoint and a later ~183-day timepoint.
What delivery and administration-form limitations are added (intrathecal bolus, needle, concentration, volume)?
Claim 4 and 14: intrathecal bolus
Claim 4: “intrathecal bolus injection.”
Claim 14 repeats the same dependent structure for claim 2.
These are route-adjacent limitations. If a competitor’s administration method differs (for example, infusion rather than bolus) it could argue noninfringement for those dependent claims, while still potentially implicating claim 1 if claim 1’s “intrathecal injection” is interpreted broadly enough to cover non-bolus forms.
Claim 7 and 17: spinal anesthesia needle
Claim 7: administration using a spinal anesthesia needle.
Claim 17 repeats for claim 2.
This is a delivery-tool limitation. It is valuable for infringement tactics if actual commercial administration uses spinal anesthesia needles as standard-of-care or as part of a labeled technique, but it is also a potential design-around lever if alternative intrathecal delivery devices are used.
Claim 8 and 18: concentration limitation (2.4 mg/mL)
Claim 8: concentration is 2.4 mg/mL.
Claim 18 repeats for claim 2.
This is a formulation-level numeric constraint that can be used as an infringement carve-out if a product uses a different concentration (even if the dose amount and total volume differ).
Claim 9 and 19: injection volume limitation (5.0 mL)
Claim 9: injection volume is 5.0 mL.
Claim 19 repeats for claim 2.
This can be tightly coupled with claim 8. For an accused product, meeting “12 mg” at “2.4 mg/mL” naturally implies 5.0 mL volume (12 mg ÷ 2.4 mg/mL = 5 mL). The patent appears to align these numeric parameters as a consistent dose formulation. That alignment strengthens the dependence chain.
What patient subpopulations are covered (SMA type I–IV and age windows)?
Claim 5 and 15: SMA type I–IV
Claim 5 lists:
- type I, II, III, or IV SMA.
These are broad. They are not limited by SMN2 copy number, prior therapies, or disease stage within the claim language you provided.
Claim 15 mirrors claim 5 for claim 2 dependency.
Claim 6 and 16: broad age range
Claim 6 states the antisense compound is administered when the subject is:
- between 1 and 15 years of age, or
- less than one week old, or
- less than one month old, or
- less than 3 months old, or
- less than 6 months old, or
- less than one year old, or
- less than 2 years old, or
- older than 15 years old.
This is a broad age inclusion list that effectively covers almost all practical pediatric-to-adult age categories. The redundancies (less than one week includes less than one month, etc.) broaden capture rather than narrow.
Claim 16 repeats the same dependency for claim 2.
How many distinct claim “coverage buckets” exist and what do they cover?
Based on the independent claim and the dependent claim themes, there are at least five functional coverage buckets:
-
Molecule identity bucket (hard constraint)
- 18-linked nucleosides
- SEQ ID NO:1
- phosphorothioate linkages
- 2′-MOE nucleosides
- 5-methylcytosine cytosines
-
Induction regimen bucket
- 12 mg dosing
- second dose 12–18 days after first
- third dose 25–35 days after first
-
Embodiment induction regimen bucket
- claim 2’s approximate 15-day and 29-day anchors, aligned with claim 1’s windows
-
Maintenance schedule bucket
- claim 3: “at least one maintenance dose”
- claim 10: specific maintenance timing 178–188 days
- claim 11–12: expanded 4th and 5th dosing at ~64 and ~183 days
-
Administration/formulation bucket
- bolus injection
- spinal anesthesia needle
- concentration 2.4 mg/mL
- injection volume 5.0 mL
A method practice that matches the molecule identity plus induction regimen can still avoid some dependent claims by changing bolus technique, needle type, concentration, or volume, but it remains exposed to claim 1 unless those changes alter “intrathecal injection doses” and dose timing/amount.
What claim scope is most vulnerable to design-around: timing vs chemistry vs concentration?
Chemistry/sequence is the hardest design-around
Claim 1’s oligonucleotide identity is extremely specific:
- sequence (SEQ ID NO:1),
- backbone (phosphorothioate),
- sugar (2′-MOE),
- cytosine modification (5-methyl cytosine),
- length (18-linked nucleosides).
Any competitor attempting to keep dosing regimen but use a different antisense molecule must depart from at least one of these descriptors. That typically drives high R&D costs and regulatory burden.
Timing windows are a moderate design-around lever
Claim 1 uses ranges (12–18 and 25–35 days). Design-around could attempt:
- second dose outside 12–18,
- third dose outside 25–35.
But claim 11–12 and claim 10 and the “approximately” timing anchored claims increase the risk that alternative regimens are still captured.
Concentration and volume are the most feasible operational levers
Because claim 8/18 (2.4 mg/mL) and claim 9/19 (5.0 mL) recite explicit numeric parameters, a competitor may attempt to use:
- different concentration and volume while keeping the total dose at 12 mg, or
- different total volume delivery strategies.
However, since 12 mg and 2.4 mg/mL mathematically ties to 5 mL, practical dose formulation changes may cascade into administration constraints and could still implicate other dependent claims if bolus technique and needle method remain the same.
What does the claim set imply about the underlying active ingredient class (Smn2-targeted antisense oligonucleotide vs other approaches)?
Claim 1’s structure points to a chemically modified antisense oligonucleotide with:
- 2′-MOE modifications and phosphorothioate backbone,
- 5-methylcytosine,
- 18-mer length,
- defined sequence identity (SEQ ID NO:1).
That chemistry pattern is characteristic of clinical antisense therapeutics used to modulate SMN2 splicing in SMA programs. The patent language you supplied, however, does not include functional target wording (for example, “SMN2” or “splicing”) in the claims excerpt. The claim scope is therefore framed around method practice plus molecule identity, not around a mechanistic target term.
How strong is the patent estate for enforcement based on claim drafting posture?
Strength drivers
- Single independent claim with broad patient coverage and explicit dosing schedule windows.
- High specificity of the oligonucleotide identity narrows infringement analysis but also increases validity defensibility against overbroad interpretation.
- Dependent claims layer on common operational constraints (bolus injection, needle type) and formulation numerics (2.4 mg/mL; 5 mL).
- Maintenance dosing is covered by both generic (“at least one maintenance dose”) and specific timing embodiments (64, 178–188, 183 days).
Enforcement strategy implications
- Litigation leverage is strongest against competitors whose clinical dosing protocol is aligned to the same regimen structure and whose formulation uses the same concentration/volume.
- Defendants can attempt to position around any one of the “hard points” (intrathecal delivery method, dosing timeline, molecule identity chemistry or concentration/volume). But because claim 1 already requires intrathecal injection with a multi-dose induction schedule, any divergence must be meaningful.
What patent landscape questions remain unanswerable from claims alone (but affect freedom-to-operate)?
The claims provided define one patent. A complete US landscape for SMA intrathecal 18-mer 2′-MOE antisense programs typically includes additional:
- earlier priority claims to the oligonucleotide sequence and chemistry,
- formulation and delivery device patents,
- method-of-use variants,
- manufacturing-process patents,
- continuation/divisional family members with adjusted dosing windows or maintenance schedules,
- regulatory exclusivity and Orange Book/Tertiary listings.
Your prompt requests “detailed analysis of the scope and claims and patent landscape,” but only the claims for 10,436,802 are provided. Without bibliographic and family metadata, and without the Orange Book or litigation records tied to this specific patent, a comprehensive landscape map across US assignees, expirations, and relevant competing patents cannot be produced with the level of factual precision required for business decisions.
Key Takeaways
- US Patent 10,436,802 is a method-of-treatment patent requiring intrathecal injection of a precisely defined 18-mer antisense oligonucleotide (SEQ ID NO:1; phosphorothioate linkages; 2′-MOE sugars; 5-methylcytosine) plus a 12 mg induction regimen with dosing windows of 12–18 days (dose 2) and 25–35 days (dose 3) after the first dose.
- Dependent claims add enforcement hooks on approximate induction anchors (15 and 29 days), maintenance dosing (including 178–188 days and additional doses around 64 and 183 days), and operational/formulation parameters (intrathecal bolus, spinal anesthesia needle, 2.4 mg/mL, 5.0 mL).
- Patient scope is broad: SMA type I–IV and an age range that effectively spans infants through adults.
- The most practical design-around levers are concentration/volume and delivery form; the hardest is changing the antisense molecule identity and the induction timing windows captured in claim 1.
FAQs
1) If a competitor uses intrathecal antisense but a different second-dose interval (outside 12–18 days), does claim 1 avoid infringement?
It avoids claim 1’s induction regimen as written, but dependent claims with “approximately” timing may still present overlap if their schedules land within those dependent claim windows.
2) Does claim 1 require “bolus” delivery or only “intrathecal injection”?
Claim 1 requires “intrathecal injection.” “Intrathecal bolus injection” appears in dependent claims (4 and 14).
3) Can a different concentration avoid dependent claims 8/18 while still meeting 12 mg per dose?
Yes, because claims 8 and 18 explicitly require 2.4 mg/mL. If concentration differs while maintaining 12 mg dose and other claim 1 elements, dependent claims 8/18 would not be met.
4) Are maintenance doses optional in claim 1?
Claim 1 does not require maintenance doses. Maintenance is introduced in dependent claims (3, 10, 11, 12, 13, 20).
5) Is age a limiting factor in these claims?
No. Claims 6 and 16 list a broad set of age categories that collectively cover essentially all practical ages.
